

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

Amerigen Pharmaceuticals Limited and Argentum Pharmaceuticals LLC

Petitioners

v.

Janssen Oncology, Inc.

Patent Owner

U.S. Patent No. 8,822,438 to Auerbach et al.


Issue Date: September 2, 2014

Title: Methods and Compositions for Treating Cancer


Inter Partes Review No. 2016-00286¹

Declaration of Dr. Richard I. Dorin

I declare that all statements made herein on my own knowledge are true and that all statements made on information and belief are believed to be true, and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code.



Richard I. Dorin, M.D.



Date

¹ Case IPR2016-01317 has been joined with this proceeding.

AMERIGEN 1093

Table of Contents

I.	Introduction	1
II.	Education and Professional Background	1
III.	Legal Standards	3
IV.	Summary of Opinions	4
	A. AA administered to humans inhibits BOTH 17-hydroxylase and 17,20-lyase activities.	4
	B. Among the spectrum of P450c17 deficiency syndromes related to mutations in the P450c17 gene, the subtype designated as combined, partial 17-hydroxylase/17,20-lyase deficiency is the most relevant and appropriate for analogy in relation to men receiving long-term AA.	5
	C. I disagree with Dr. Auchus’ conclusion (paragraph 58) that the relevant analogy between AA and P450c17 deficiency would be “isolated 17,20-lyase” deficiency (Auchus paragraph 58).	9
	D. A POSA would conclude that there is a substantial risk for clinically relevant cortisol deficiency in men with mCRPC treated long term with AA.	9
	E. POSA would conclude that there is a substantial risk for development of mineralocorticoid excess in men with mCRPC treated with long-term AA, and that “concomitant administration of replacement glucocorticoid” would be a reasonable, safe, and appropriate management strategy for prevention and treatment of mineralocorticoid excess.	13
	F. POSA would recognize the safety of “concomitant administration of replacement glucocorticoid” in the study population of men with mCRPC.	17
V.	DEFINITIONS	22
VI.	DETAILED ANALYSIS OF OPINIONS	23
	A. Background.	23
	B. Cortisol Levels and the Synacthen Test.	24
	1. Timing of cortisol collection in the standard ACTH1-24 stimulation test	24

2.	Baseline, peak, and Δ -cortisol.....	25
3.	The standard, high-dose (250 μ g) and low dose (1 μ g) ACTH1-24 stimulation tests	26
4.	Cut-scores used for the clinical diagnosis of adrenal insufficiency	27
5.	ACTH1-24-stimulated cortisol concentration is less influenced by time of day than Δ -cortisol.....	27
C.	Study C in O'Donnell	28
1.	ACTH1-24 stimulation testing before and after 11 days of once daily AA	28
2.	Post-AA mean Δ -cortisol values are markedly reduced compared to pre-AA Δ -cortisol values, and post-AA Δ -cortisol are markedly reduced compared to established reference ranges	29
3.	Δ -cortisol is similarly decreased in AA-treated subjects and in patients with 17-hydroxylase/17,20-lyase deficiency	30
4.	Dr. Auchus' dismissal of Δ -cortisol data in O'Donnell (Study C) is not justified.....	31
5.	Dr. Auchus' objection that O'Donnell presentation of cortisol data as mean without measure of variability is sustained, but this omission does not influence the POSA's interpretation of Study C	31
6.	Dr. Auchus' concern that the dose of Synacthen (1 vs. 250 μ g) used in Study C was not specified is invalid but, regardless, would not influence interpretation of Δ -cortisol data.....	33
7.	Dr. Auchus' concern that time of day that the Synacthen test was performed was not specified is invalid but, regardless, would not influence interpretation of Δ -cortisol data.....	35
8.	Dr. Auchus argument (paragraph 28) that O'Donnell presentation of cortisol data in Study should have included peak cortisol instead of or in addition to Δ -cortisol is sustained, but the omission of peak cortisol concentration data does not invalidate or influence POSA's interpretation of Study C.....	36
9.	Summary of Study C analysis.....	39

- D. Endocrine data for single dose studies (Studies A and B) in O’Donnell would not dissuade a POSA from the conclusion that “adrenocortical suppression may necessitate concomitant administration of replacement glucocorticoid” in patients treated with long-term AA 40
- E. The absence of overt manifestations of adrenal insufficiency during clinical event monitoring data reported in O’Donnell (“Overall Toxicity” section) would not dissuade a POSA from the conclusion that “adrenocortical suppression may necessitate concomitant administration of replacement glucocorticoid” in patients treated with long-term AA 43
- F. The absence of overt manifestations of mineralocorticoid excess during clinical event monitoring data reported in O’Donnell (“Overall Toxicity” section) would not dissuade a POSA from the conclusion that concomitant administration of replacement glucocorticoid is indicated in patients treated with long-term AA
46

I, Richard I. Dorin, M.D., do hereby declare:

I. Introduction

1. At the request of Petitioners Amerigen Pharmaceuticals, Ltd. and Argentum Pharmaceuticals, LLC (“Petitioners”) in the matter of the *inter partes* review of U.S. Patent No. 8,822,438 (the “438 Patent” (AMG 1001), requested by Petitioners and instituted by Patent Trial and Appeal Board of the United States Patent and Trademark Office in Case No. IPR2016-00286 and Case No. IPR2016-01317, I have been asked to provide my opinions regarding the expert declaration and deposition testimony of Richard Auchus, M.D., Ph.D., submitted on behalf of Patent Owner Janssen Oncology, Inc. (“Janssen”).

2. I am being compensated for my work in this matter at the rate of \$400.00 per hour. My compensation in no way depends on the outcome of this proceeding. The opinions I set forth herein are my own, and are based on the education, experience, training and skill that I have accumulated in the course of my career as a physician and researcher, as well as the materials I have reviewed in connection with this case.

II. Education and Professional Background

3. I currently practice medicine at the New Mexico Veterans Administration Healthcare System in Albuquerque, New Mexico. I am also a Professor of Medicine and Biochemistry & Molecular Biology at the University of

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.